{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:45:54Z","timestamp":1785321954130,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s10637-022-01259-x","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T08:03:38Z","timestamp":1653465818000},"page":"1133-1136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046"],"prefix":"10.1007","volume":"40","author":[{"given":"Matteo","family":"Repetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1869-0607","authenticated-orcid":false,"given":"Edoardo","family":"Crimini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Ascione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Boscolo Bielo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Belli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"issue":"8","key":"1259_CR1","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1093\/ANNONC\/MDY137","volume":"29","author":"V Subbiah","year":"2018","unstructured":"Subbiah V et al (2018) Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol 29(8):1869. https:\/\/doi.org\/10.1093\/ANNONC\/MDY137","journal-title":"Ann Oncol"},{"issue":"9","key":"1259_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMOA2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth LJ et al (2020) Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med 383(9):825\u2013835. https:\/\/doi.org\/10.1056\/NEJMOA2005651","journal-title":"N Engl J Med"},{"issue":"3","key":"1259_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/J.ANNONC.2020.11.021","volume":"32","author":"C Belli","year":"2021","unstructured":"Belli C et al (2021) ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann Oncol Off J Eur Soc Med Oncol 32(3):337\u2013350. https:\/\/doi.org\/10.1016\/J.ANNONC.2020.11.021","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"7","key":"1259_CR4","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","volume":"22","author":"JF Gainor","year":"2021","unstructured":"Gainor JF et al (2021) Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study. Lancet Oncol 22(7):959\u2013969. https:\/\/doi.org\/10.1016\/S1470-2045(21)00247-3","journal-title":"Lancet Oncol"},{"issue":"8","key":"1259_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","volume":"9","author":"V Subbiah","year":"2021","unstructured":"Subbiah V et al (2021) \u201cPralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study\u201d, lancet. Diabetes Endocrinol 9(8):491\u2013501. https:\/\/doi.org\/10.1016\/S2213-8587(21)00120-0","journal-title":"Diabetes Endocrinol"},{"issue":"9","key":"1259_CR6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMOA2005653","volume":"383","author":"A Drilon","year":"2020","unstructured":"Drilon A et al (2020) Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med 383(9):813\u2013824. https:\/\/doi.org\/10.1056\/NEJMOA2005653","journal-title":"N Engl J Med"},{"issue":"7","key":"1259_CR7","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","volume":"8","author":"V Subbiah","year":"2018","unstructured":"Subbiah V et al (2018) Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov 8(7):836\u2013849. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0338","journal-title":"Cancer Discov"},{"issue":"2","key":"1259_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/J.ANNONC.2020.10.599","volume":"32","author":"V Subbiah","year":"2021","unstructured":"Subbiah V et al (2021) Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol Off J Eur Soc Med Oncol 32(2):261\u2013268. https:\/\/doi.org\/10.1016\/J.ANNONC.2020.10.599","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1259_CR9","doi-asserted-by":"publisher","first-page":"v190","DOI":"10.1093\/ANNONC\/MDZ244.068","volume":"30","author":"A Drilon","year":"2019","unstructured":"Drilon A et al (2019) TPX-0046 is a novel and potent RET\/SRC inhibitor for RET-driven cancers. Ann Oncol 30:v190\u2013v191. https:\/\/doi.org\/10.1093\/ANNONC\/MDZ244.068","journal-title":"Ann Oncol"},{"issue":"1","key":"1259_CR10","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1158\/1078-0432.CCR-19-1104","volume":"26","author":"G Recondo","year":"2020","unstructured":"Recondo G et al (2020) Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. Clin Cancer Res 26(1):242\u2013255. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1104","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1259_CR11","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.21037\/TLCR-20-372","volume":"9","author":"F Tabb\u00f2","year":"2020","unstructured":"Tabb\u00f2 F, Reale ML, Bironzo P, Scagliotti GV (2020) Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won. Transl lung cancer Res 9(6):2545\u20132556. https:\/\/doi.org\/10.21037\/TLCR-20-372","journal-title":"Transl lung cancer Res"},{"issue":"6","key":"1259_CR12","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","volume":"8","author":"S Yoda","year":"2018","unstructured":"Yoda S et al (2018) Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov 8(6):714\u2013729. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1256","journal-title":"Cancer Discov"},{"key":"1259_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/J.EBIOM.2019.01.019","volume":"41","author":"K Okada","year":"2019","unstructured":"Okada K et al (2019) Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. EBioMedicine 41:105\u2013119. https:\/\/doi.org\/10.1016\/J.EBIOM.2019.01.019","journal-title":"EBioMedicine"},{"issue":"10","key":"1259_CR14","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1158\/1078-0432.CCR-21-0032","volume":"27","author":"JJ Lin","year":"2021","unstructured":"Lin JJ et al (2021) Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. Clin Cancer Res 27(10):2899\u20132909. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0032","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1259_CR15","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1021\/CI500588J","volume":"55","author":"T Sander","year":"2015","unstructured":"Sander T, Freyss J, Von Korff M, Rufener C (2015) DataWarrior: An Open-Source Program For Chemistry Aware Data Visualization And Analysis. J Chem Inf Model 55(2):460\u2013473. https:\/\/doi.org\/10.1021\/CI500588J","journal-title":"J Chem Inf Model"},{"issue":"2","key":"1259_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/JCC.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ (2010) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455\u2013461. https:\/\/doi.org\/10.1002\/JCC.21334","journal-title":"J Comput Chem"},{"issue":"12 Supplement","key":"1259_CR17","doi-asserted-by":"publisher","first-page":"P233","DOI":"10.1158\/1535-7163.TARG-21-P233","volume":"20","author":"I Odintsov","year":"2021","unstructured":"Odintsov I et al (2021) Abstract P233: TAS0953\/HM06 is effective in preclinical models of diverse tumor types driven by RET alterations. Mol Cancer Ther 20(12 Supplement):P233\u2013P233. https:\/\/doi.org\/10.1158\/1535-7163.TARG-21-P233","journal-title":"Mol Cancer Ther"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01259-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-022-01259-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01259-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:48:07Z","timestamp":1678510087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-022-01259-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1259"],"URL":"https:\/\/doi.org\/10.1007\/s10637-022-01259-x","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"GC: Consultancy with Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Foundation Medicine, GlaxoSmithKline, Lilly, Novartis, Pfizer, Roche\/Genentech, Samsung, and Seagen Inc.; honoraria from Ellipses Pharma; research funding\/grants from Merck; speaker\u2019s bureau with Daiichi Sankyo, Foundation Medicine, Lilly, Novartis, Pfizer, Roche\/Genentech, Samsung, and Seagen Inc.; travel from Pfizer and Roche\/Genentech. Other authors have no conflicts of interest to declare.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}